Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXDXNASDAQ:BNGONASDAQ:LABNASDAQ:OMIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXDXAccelerate Diagnostics$0.65$0.03▼$2.09$857K0.22509,433 shs53.64 million shsBNGOBionano Genomics$3.32+1.8%$3.86$2.68▼$52.20$11.17M2.27108,167 shs74,848 shsLABStandard BioTools$1.09+6.9%$1.09$0.92▼$2.41$414.01M1.52.08 million shs1.57 million shsOMICSingular Genomics Systems$20.01$20.01$5.34▼$23.41$50.83M1.8348,538 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXDXAccelerate Diagnostics0.00%0.00%0.00%-96.18%-96.51%BNGOBionano Genomics0.00%-10.27%-11.94%+2.15%-92.86%LABStandard BioTools0.00%+3.81%+3.81%-9.92%-46.83%OMICSingular Genomics Systems0.00%0.00%0.00%0.00%+102.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXDXAccelerate Diagnostics0.9467 of 5 stars0.00.00.04.70.02.50.6BNGOBionano Genomics0.9778 of 5 stars3.11.00.00.00.60.00.6LABStandard BioTools2.3178 of 5 stars3.32.00.00.00.03.31.3OMICSingular Genomics SystemsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXDXAccelerate Diagnostics 4.00Strong BuyN/AN/ABNGOBionano Genomics 2.25Hold$7.00110.84% UpsideLABStandard BioTools 2.50Moderate Buy$2.50129.36% UpsideOMICSingular Genomics Systems 2.00Hold$6.50-67.52% DownsideCurrent Analyst Ratings BreakdownLatest LAB, BNGO, AXDX, and OMIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025BNGOBionano GenomicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/2/2025BNGOBionano GenomicsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$1.00 ➝ $4.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXDXAccelerate Diagnostics$11.70M0.00N/AN/A($1.37) per share0.00BNGOBionano Genomics$30.78M0.36N/AN/A$18.12 per share0.18LABStandard BioTools$169.69M2.44N/AN/A$1.27 per share0.86OMICSingular Genomics Systems$2.91M17.47N/AN/A$73.25 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXDXAccelerate Diagnostics-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/ABNGOBionano Genomics-$112.02M-$138.92N/A∞N/A-294.05%-125.75%-71.96%8/6/2025 (Estimated)LABStandard BioTools-$138.88M-$0.35N/AN/AN/A-78.24%-22.44%-16.74%7/30/2025 (Estimated)OMICSingular Genomics Systems-$94.82M-$35.11N/A∞N/A-3,237.89%-57.87%-37.90%8/12/2025 (Estimated)Latest LAB, BNGO, AXDX, and OMIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BNGOBionano Genomics-$3.49-$1.15+$2.34-$1.15$6.25 million$6.46 million3/20/2025Q4 2024AXDXAccelerate Diagnostics-$0.50-$0.37+$0.13-$0.37$3.00 million$2.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXDXAccelerate DiagnosticsN/AN/AN/AN/AN/ABNGOBionano GenomicsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/AOMICSingular Genomics SystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXDXAccelerate DiagnosticsN/A1.501.34BNGOBionano Genomics0.071.701.34LABStandard BioToolsN/A6.125.37OMICSingular Genomics Systems0.047.376.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXDXAccelerate Diagnostics17.14%BNGOBionano Genomics11.35%LABStandard BioTools53.74%OMICSingular Genomics Systems65.80%Insider OwnershipCompanyInsider OwnershipAXDXAccelerate Diagnostics43.60%BNGOBionano Genomics0.90%LABStandard BioTools23.16%OMICSingular Genomics Systems22.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXDXAccelerate Diagnostics22025.21 million14.13 millionOptionableBNGOBionano Genomics3003.36 million3.33 millionOptionableLABStandard BioTools620379.82 million291.86 millionOptionableOMICSingular Genomics Systems2202.54 million1.97 millionNo DataLAB, BNGO, AXDX, and OMIC HeadlinesRecent News About These CompaniesSingular Genomics highlights G4X milestones at AGBTFebruary 24, 2025 | markets.businessinsider.comSingular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBTFebruary 24, 2025 | markets.businessinsider.comSingular Genomics announces closing of acquisition by Deerfield ManagmentFebruary 22, 2025 | markets.businessinsider.comSingular Genomics Shareholders Approve Merger AgreementFebruary 22, 2025 | investing.comSingular Genomics Systems, Inc. Closes Acquisition by Deerfield Management CompanyFebruary 21, 2025 | quiverquant.comSingular Genomics Announces Closing of Acquisition by Deerfield ManagementFebruary 21, 2025 | globenewswire.comSingular Genomics Systems IncFebruary 20, 2025 | morningstar.comAndrew Spaventa Sells 800 Shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) StockFebruary 15, 2025 | insidertrades.comSingular genomics CEO sells shares worth $15,912February 14, 2025 | msn.comSingular Genomics faces lawsuits over merger disclosuresFebruary 13, 2025 | msn.com(OMIC) Trading ReportFebruary 11, 2025 | news.stocktradersdaily.comGenomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Impacting Market Trends - TechnavioJanuary 31, 2025 | uk.finance.yahoo.comInvestors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities FraudJanuary 30, 2025 | accessnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach OutJanuary 29, 2025 | accessnewswire.comOMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law FirmJanuary 28, 2025 | prnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach OutJanuary 27, 2025 | accessnewswire.comInvestors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities FraudJanuary 26, 2025 | accessnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach OutJanuary 25, 2025 | accessnewswire.comInvestors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities FraudJanuary 24, 2025 | accessnewswire.comSingular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach OutJanuary 23, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Buy-and-Hold-Forever Stocks Available at a BargainBy Nathan Reiff | June 16, 2025View 4 Buy-and-Hold-Forever Stocks Available at a BargainGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?5 Stocks Set to Soar This SummerBy Ryan Hasson | June 2, 2025View 5 Stocks Set to Soar This SummerRocket Lab Expands Into Payloads: Should You Be Paying Attention?By Ryan Hasson | June 3, 2025View Rocket Lab Expands Into Payloads: Should You Be Paying Attention?LAB, BNGO, AXDX, and OMIC Company DescriptionsAccelerate Diagnostics NASDAQ:AXDX$0.04 +0.04 (+∞) As of 05/14/2025 This is a fair market value price provided by Polygon.io. Learn more.Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.Bionano Genomics NASDAQ:BNGO$3.32 +0.06 (+1.84%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.28 -0.04 (-1.20%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.Standard BioTools NASDAQ:LAB$1.09 +0.07 (+6.86%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.11 +0.02 (+1.74%) As of 06/18/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Singular Genomics Systems NASDAQ:OMIC$20.01 0.00 (0.00%) As of 02/21/2025Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
